<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683995</url>
  </required_header>
  <id_info>
    <org_study_id>2246-0703</org_study_id>
    <nct_id>NCT00683995</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Study of KW-2246</brief_title>
  <official_title>A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as&#xD;
      rescue medication for breakthrough pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pain, Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-2246 (fentanyl citrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-2246 (fentanyl citrate)</intervention_name>
    <description>KW-2246 (fentanyl citrate)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent to participate in the study on a voluntary basis.&#xD;
&#xD;
          -  Patients who have been eligible for the confirmatory trial by meeting the inclusion&#xD;
             criteria applicable at the time of giving written informed consent and those&#xD;
             applicable at the time of randomization, and who have completed the confirmatory&#xD;
             trial.&#xD;
&#xD;
          -  Outpatients who live with a caregiver such as a family member, or inpatients.&#xD;
&#xD;
          -  Require rescue medication at least 0.5 times (at least once every two days) but not&#xD;
             more than three times per day on average as determined by the investigator.&#xD;
&#xD;
          -  Performance Status (ECOG) of 3 or less at the time of giving written informed consent.&#xD;
&#xD;
          -  Have a life expectancy of at least three months as determined by the investigator.&#xD;
&#xD;
          -  Be able to receive diary training and have been able to properly complete diaries&#xD;
             during the confirmatory trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have experienced intolerable adverse reactions (as defined in Attachment 3) during the&#xD;
             confirmatory trial.&#xD;
&#xD;
          -  Have met any of the exclusion criteria applicable at the time of giving written&#xD;
             informed consent, those applicable at the time of randomization, or subject withdrawal&#xD;
             criteria in the confirmatory trial.&#xD;
&#xD;
          -  Serious respiratory dysfunction.&#xD;
&#xD;
          -  Asthma.&#xD;
&#xD;
          -  Serious bradyarrhythmia.&#xD;
&#xD;
          -  Serious hepatic dysfunction.&#xD;
&#xD;
          -  Serious renal dysfunction.&#xD;
&#xD;
          -  Susceptibility to respiratory depression due to conditions such as increased&#xD;
             intracranial pressure, head injury and brain tumor.&#xD;
&#xD;
          -  Patients who have a history of clinically significant adverse reactions to the&#xD;
             combination of opioid analgesics and any of the following drugs/substances, and who&#xD;
             are currently receiving or expect to receive any of them during the study:&#xD;
&#xD;
        Central nervous system depressants (phenothiazines, benzodiazepines and barbiturates),&#xD;
        inhalation anesthetics, monoamine oxidase inhibitors, tricyclic antidepressants, skeletal&#xD;
        muscle relaxants, antihistamines, ritonavir, alcohol, itraconazole, amiodarone,&#xD;
        clarithromycin, diltiazem, and fluvoxamine.&#xD;
&#xD;
          -  History of convulsive seizures (except a single episode of infantile febrile&#xD;
             convulsions).&#xD;
&#xD;
          -  History of hypersensitivity to fentanyl.&#xD;
&#xD;
          -  Pregnant or lactating women, possibly pregnant women, or women who are planning to&#xD;
             become pregnant.&#xD;
&#xD;
          -  Patients who are judged by the investigator/subinvestigator to be inappropriate for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Kirin Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katori</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azumino</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mibu</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

